Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2009

View Archived Issues

Ariad presents first interim analysis of phase III ridaforolimus trial in metastatic sarcoma

Protox Therapeutics presents 12-month phase II PRX-302 results

Mpex reports phase II results with Aeroquin, delivered by eFlow technology

Salix reports results for rifaximin in non-constipation irritable bowel syndrome

Vical's influenza vaccine demonstrates cross-reactivity against H1N1 strains

Aeolus initiates second AEOL-10150 study as a countermeasure to radiation

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Esperance commences clinical studies of EP-100 in cancer

Diabetes Research Centers collaborate on phase II Exsulin trial

Protalix BioTherapeutics completes pivotal phase III prGCD trial for Gaucher's disease

Combined tamibarotene and arsenic trioxide to be studied for acute promyelocytic leukemia

FDA approves four influenza A (H1N1) 2009 monovalent vaccines

PAR1 antagonists for the treatment of thrombosis disclosed by sanofi-aventis

Novel renin inhibitors in development at sanofi-aventis for the treatment of hypertension

Follicle-stimulating hormone receptor activators for female infertility disclosed by Organon

Noscira claims novel beta-secretase 1 and GSK-3beta inhibitors for AD

Boehringer Ingelheim discloses EGFR inhibitors for the treatment of cancer

Duloxetine produces sustained pain reduction in patients with chronic low back pain

Population PK/PD modeling predicts optimal dosing regimen of TV-1102

Integrin receptor antagonist GLPG-0187 inhibits metastatic tumor growth and bone tumor burden

In vivo anti-ulcerative activity exhibited by chitosan

BL-1020 meets primary and secondary endpoints in phase IIb EAGLE trial

Panobacumab safe in patients with hospital-acquired pneumonia

Phase I data show MGCD-290 to be well tolerated, with favorable pharmacokinetics

Ascenta Therapeutics obtains clearance by the FDA for its IND application for AT-406

Biotie Therapies commences clinical study with phosphodiesterase 4 inhibitor ELB-353

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...